Final notification for inclusion of Acitretin in schedule H of the Drugs Rules 1945

## Policy Analysis Report: Drugs Fourth Amendment Rules, 2022 **1. Executive Summary:** This report analyzes the Drugs Fourth Amendment Rules, 2022, as notified by the Ministry of Health and Family Welfare, Department of Health and Family Welfare, Government of India, on May 18, 2022. This amendment to the Drugs Rules, 1945, introduces Acitretin into Schedule H as entry number 552. The amendment aims to update and expand the list of drugs included in Schedule H, impacting pharmaceutical manufacturers, distributors, and healthcare professionals involved with Acitretin. This report provides an overview of the amendment, its background, key changes, and potential implications. **2. Introduction:** This report aims to provide a comprehensive analysis of the Drugs Fourth Amendment Rules, 2022, based on the official notification published in the Gazette of India on May 18, 2022. The analysis focuses on understanding the purpose, changes introduced, and potential impact of this amendment on the existing Drugs Rules, 1945. **3. Policy Overview:** * **Original Policy Being Amended:** Drugs Rules, 1945 * **Core Objective(s):** (Inferred from the text) To regulate the manufacturing, distribution, and sale of drugs and cosmetics in India. This is inferred as the text amends the Drugs Rules of 1945 and mentions the Drugs and Cosmetics Act, 1940. **4. Background and Rationale:** The amendment likely aims to update the Drugs Rules, 1945, to include Acitretin in Schedule H. Schedule H lists drugs that can only be sold by retail on the prescription of a Registered Medical Practitioner. The rationale for adding Acitretin to this schedule is likely due to its potential side effects or the need for medical supervision during its use. This ensures that Acitretin is only used under proper medical guidance, protecting public health. **5. Key Provisions / Changes:** * **Specific Part of the Original Policy Being Changed:** Schedule H of the Drugs Rules, 1945. * **New Rule/Provision:** Insertion of serial number 552 with the entry "Acitretin" into Schedule H. * **Difference/Effect of the Change:** This amendment places Acitretin under the regulatory control of Schedule H, meaning it can now only be sold with a prescription from a registered medical practitioner. Previously, its sale might not have been restricted in this way. This change directly impacts the availability and distribution of Acitretin, requiring stricter controls and medical oversight. **6. Target Audience and Stakeholders:** The primary target audience and stakeholders include: * Pharmaceutical manufacturers of Acitretin products. * Distributors and retailers of Acitretin. * Healthcare professionals, particularly dermatologists, prescribing Acitretin. * Patients using Acitretin, who will now require a prescription to obtain it. * Regulatory bodies responsible for enforcing the Drugs and Cosmetics Act, 1940. **7. Implementation Aspects (Inferred):** * **Responsible Agency/Bodies:** The Ministry of Health and Family Welfare, Department of Health and Family Welfare, and the Drugs Technical Advisory Board are involved in the implementation, oversight, and enforcement of this amendment. * **Timelines:** The amendment comes into force on November 1st, 2022. * **Specific to the changes:** Distributors and retailers will need to ensure they only sell Acitretin with a valid prescription after the effective date. Manufacturers will need to update their labeling and packaging to reflect the Schedule H status. **8. Expected Outcomes / Impact of Changes:** The likely intended outcome of this amendment is to: * Ensure the responsible use of Acitretin by requiring a prescription for its sale. * Reduce the potential for misuse or overuse of Acitretin. * Protect patient safety by ensuring medical supervision during Acitretin treatment. * Increase the administrative burden associated with stocking, prescribing, and dispensing Acitretin. **9. Conclusion:** The Drugs Fourth Amendment Rules, 2022, represent a regulatory update to the Drugs Rules, 1945, by adding Acitretin to Schedule H. This change necessitates prescription-only sales of Acitretin, with the likely intention of ensuring safer and more responsible use of the drug. Affected stakeholders, including pharmaceutical companies, distributors, healthcare professionals, and patients, must understand and comply with the new regulations from November 1st, 2022. The implementation and enforcement of this amendment will be crucial in achieving its intended outcomes of improved patient safety and responsible drug usage.

Key Entities Referenced